CALUMET SPECIALTY PRODUCTS (CLMT)

US1314761032

16.2  +0.27 (+1.69%)

After market: 16.29 +0.09 (+0.56%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to CLMT. CLMT was compared to 214 industry peers in the Oil, Gas & Consumable Fuels industry. CLMT may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, CLMT is valued expensive at the moment.



Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year CLMT was profitable.
In the past year CLMT has reported a negative cash flow from operations.
In the past 5 years CLMT reported 4 times negative net income.
In multiple years CLMT reported negative operating cash flow during the last 5 years.

1.2 Ratios

The Return On Assets of CLMT (1.71%) is worse than 73.36% of its industry peers.
With a decent Return On Invested Capital value of 13.05%, CLMT is doing good in the industry, outperforming 69.63% of the companies in the same industry.
Industry RankSector Rank
ROA 1.71%
ROE N/A
ROIC 13.05%
ROA(3y)-5.39%
ROA(5y)-5.31%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

With a Profit Margin value of 1.13%, CLMT is not doing good in the industry: 75.70% of the companies in the same industry are doing better.
CLMT's Operating Margin of 6.47% is on the low side compared to the rest of the industry. CLMT is outperformed by 76.64% of its industry peers.
CLMT's Operating Margin has improved in the last couple of years.
CLMT's Gross Margin of 10.80% is on the low side compared to the rest of the industry. CLMT is outperformed by 75.70% of its industry peers.
CLMT's Gross Margin has declined in the last couple of years.
Industry RankSector Rank
OM 6.47%
PM (TTM) 1.13%
GM 10.8%
OM growth 3YN/A
OM growth 5Y13.91%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y5.26%
GM growth 5Y-2.85%

More info and screens

0

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so CLMT is still creating some value.
The number of shares outstanding for CLMT has been increased compared to 1 year ago.
CLMT has more shares outstanding than it did 5 years ago.
CLMT has a worse debt/assets ratio than last year.

2.2 Solvency

Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z N/A
ROIC/WACC1.48
WACC8.84%

2.3 Liquidity

CLMT has a Current Ratio of 0.71. This is a bad value and indicates that CLMT is not financially healthy enough and could expect problems in meeting its short term obligations.
CLMT's Current ratio of 0.71 is on the low side compared to the rest of the industry. CLMT is outperformed by 79.91% of its industry peers.
A Quick Ratio of 0.32 indicates that CLMT may have some problems paying its short term obligations.
The Quick ratio of CLMT (0.32) is worse than 92.52% of its industry peers.
Industry RankSector Rank
Current Ratio 0.71
Quick Ratio 0.32

More info and screens

6

3. Growth

3.1 Past

CLMT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 138.73%, which is quite impressive.
The Earnings Per Share has been growing by 67.45% on average over the past years. This is a very strong growth
CLMT shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -10.79%.
Measured over the past years, CLMT shows a small growth in Revenue. The Revenue has been growing by 3.63% on average per year.
EPS 1Y (TTM)138.73%
EPS 3YN/A
EPS 5Y67.45%
EPS growth Q2Q31.4%
Revenue 1Y (TTM)-10.79%
Revenue growth 3Y22.61%
Revenue growth 5Y3.63%
Revenue growth Q2Q-2.29%

3.2 Future

Based on estimates for the next years, CLMT will show a very strong growth in Earnings Per Share. The EPS will grow by 39.49% on average per year.
CLMT is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 6.61% yearly.
EPS Next Y-95.39%
EPS Next 2Y2.51%
EPS Next 3Y26.36%
EPS Next 5Y39.49%
Revenue Next Year-2.61%
Revenue Next 2Y-0.05%
Revenue Next 3Y-3.93%
Revenue Next 5Y6.61%

3.3 Evolution

The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

A Price/Earnings ratio of 20.51 indicates a rather expensive valuation of CLMT.
Compared to the rest of the industry, the Price/Earnings ratio of CLMT indicates a slightly more expensive valuation: CLMT is more expensive than 72.90% of the companies listed in the same industry.
CLMT's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 27.73.
The Price/Forward Earnings ratio is 444.76, which means the current valuation is very expensive for CLMT.
Based on the Price/Forward Earnings ratio, CLMT is valued a bit more expensive than the industry average as 72.90% of the companies are valued more cheaply.
The average S&P500 Price/Forward Earnings ratio is at 20.41. CLMT is valued rather expensively when compared to this.
Industry RankSector Rank
PE 20.51
Fwd PE 444.76

4.2 Price Multiples

CLMT's Enterprise Value to EBITDA is on the same level as the industry average.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 8.27

4.3 Compensation for Growth

A more expensive valuation may be justified as CLMT's earnings are expected to grow with 26.36% in the coming years.
PEG (NY)N/A
PEG (5Y)0.3
EPS Next 2Y2.51%
EPS Next 3Y26.36%

More info and screens

0

5. Dividend

5.1 Amount

CLMT does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CALUMET SPECIALTY PRODUCTS

NASDAQ:CLMT (5/3/2024, 7:00:00 PM)

After market: 16.29 +0.09 (+0.56%)

16.2

+0.27 (+1.69%)

Chartmill FA Rating
GICS SectorEnergy
GICS IndustryGroupEnergy
GICS IndustryOil, Gas & Consumable Fuels
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap1.30B
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE 20.51
Fwd PE 444.76
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)0.3
Profitability
Industry RankSector Rank
ROA 1.71%
ROE N/A
ROCE
ROIC
ROICexc
ROICexgc
OM 6.47%
PM (TTM) 1.13%
GM 10.8%
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover1.52
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 0.71
Quick Ratio 0.32
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)138.73%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y-95.39%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-10.79%
Revenue growth 3Y22.61%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y